TY - JOUR
T1 - In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection
T2 - A Systematic Review and Meta-Analysis
AU - Bolotin, Shelly
AU - Osman, Selma
AU - Hughes, Stephanie L.
AU - Ariyarajah, Archchun
AU - Tricco, Andrea C.
AU - Khan, Sumaiya
AU - Li, Lennon
AU - Johnson, Caitlin
AU - Friedman, Lindsay
AU - Gul, Nazish
AU - Jardine, Rachel
AU - Faulkner, Maryrose
AU - Hahné, Susan J.M.
AU - Heffernan, Jane M.
AU - Dabbagh, Alya
AU - Rota, Paul A.
AU - Severini, Alberto
AU - Jit, Mark
AU - Durrheim, David N.
AU - Orenstein, Walter A.
AU - Moss, William J.
AU - Funk, Sebastian
AU - Turner, Nikki
AU - Schluter, William
AU - Jawad, Jaleela S.
AU - Crowcroft, Natasha S.
N1 - Funding Information:
Potential conflict of interests. M. J. received research grant funding for measles from the Bill & Melinda Gates Foundation and Gavi, The Vaccine Alliance, and was also a member on the WHO SAGE Working Group on measles and rubella. S. F. received research funding from Wellcome Trust. W. A. O. worked as unpaid consultant to Merck on revising measles vaccine production process. W. J. M. is a former member of the World Health Organization SAGE Working Group on Measles and Rubella. J. M. H. received grant funding Natural Science and Engineering Research Council of Canada. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Funding Information:
This study was performed as part of a suite of systematic reviews for the WHO and was funded by the World Health Organization (Contract Number APW201970235). A. C. T. is funded by a Tier 2 Canada Research Chair in Knowledge Synthesis.
Publisher Copyright:
© 2022 Her Majesty the Queen in Right of Canada, as represented by the Public Health Ontario,.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Background: We conducted a systematic review to assess whether measles humoral immunity wanes in previously infected or vaccinated populations in measles elimination settings. Methods: After screening 16 822 citations, we identified 9 articles from populations exposed to wild-type measles and 16 articles from vaccinated populations that met our inclusion criteria. Results: Using linear regression, we found that geometric mean titers (GMTs) decreased significantly in individuals who received 2 doses of measles-containing vaccine (MCV) by 121.8 mIU/mL (95% confidence interval [CI], -212.4 to -31.1) per year since vaccination over 1 to 5 years, 53.7 mIU/mL (95% CI, -95.3 to -12.2) 5 to 10 years, 33.2 mIU/mL (95% CI, -62.6 to -3.9), 10 to 15 years, and 24.1 mIU/mL (95% CI, -51.5 to 3.3) 15 to 20 years since vaccination. Decreases in GMT over time were not significant after 1 dose of MCV or after infection. Decreases in the proportion of seropositive individuals over time were not significant after 1 or 2 doses of MCV or after infection. Conclusions: Measles antibody waning in vaccinated populations should be considered in planning for measles elimination.
AB - Background: We conducted a systematic review to assess whether measles humoral immunity wanes in previously infected or vaccinated populations in measles elimination settings. Methods: After screening 16 822 citations, we identified 9 articles from populations exposed to wild-type measles and 16 articles from vaccinated populations that met our inclusion criteria. Results: Using linear regression, we found that geometric mean titers (GMTs) decreased significantly in individuals who received 2 doses of measles-containing vaccine (MCV) by 121.8 mIU/mL (95% confidence interval [CI], -212.4 to -31.1) per year since vaccination over 1 to 5 years, 53.7 mIU/mL (95% CI, -95.3 to -12.2) 5 to 10 years, 33.2 mIU/mL (95% CI, -62.6 to -3.9), 10 to 15 years, and 24.1 mIU/mL (95% CI, -51.5 to 3.3) 15 to 20 years since vaccination. Decreases in GMT over time were not significant after 1 dose of MCV or after infection. Decreases in the proportion of seropositive individuals over time were not significant after 1 or 2 doses of MCV or after infection. Conclusions: Measles antibody waning in vaccinated populations should be considered in planning for measles elimination.
KW - measles elimination
KW - measles immunity
KW - measles vaccination
KW - waning immunity
UR - http://www.scopus.com/inward/record.url?scp=85139376031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139376031&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiac039
DO - 10.1093/infdis/jiac039
M3 - Review article
C2 - 35417025
AN - SCOPUS:85139376031
SN - 0022-1899
VL - 226
SP - 1127
EP - 1139
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 7
ER -